Latest News - Stryker Corporation
Top Corporates Hub
Stryker Corporation
Stryker (SYK) Stock Could Be Cheap After Its 26% Slide
08.10.2026 04:31
Stryker has seen its share price slide over the past year, and a planned CEO transition has added a fresh storyline for investors to absorb. The question now is whether the current US$275.40 price tag is aligned with the cash flows the business is expected to generate. The stock has fallen 25.8% over the past year, which puts a sharper focus on whether that decline has brought the valuation closer to what its cash flows can justify. The planned handover from long-serving CEO Kevin Lobo to...
Barclays Initiates Coverage On Stryker with Overweight Rating, Announces Price Target of $375
07.10.2026 09:13
Barclays analyst Christopher Pasquale initiates coverage on Stryker (NYSE:SYK) with a Overweight rating and announces Price Target of $375.
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?
07.10.2026 00:00
Stryker Corporation (NYSE:SYK) traded at around $280 on October 6, 22.75% lower over twelve months. Boston Scientific Corporation (NYSE:BSX) traded near $42 over the same session, down 55.79% across the year and within sixty cents of its 52-week low. Boston Scientific reports the better margins of the two, which makes the larger fall the thing […]
Stryker: This Dividend Aristocrat Is Finally Cheap Again
05.10.2026 07:30
Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. Learn more about SYK stock here.
Stryker (SYK) Expanded Its Foot And Ankle Portfolio
22.09.2026 10:14
Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
Stryker (SYK) Expanded Its Foot And Ankle Portfolio
22.09.2026 10:14
Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
Canaccord Genuity Maintains Buy on Stryker, Lowers Price Target to $385
18.09.2026 08:35
Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $400 to $385.
Stryker stock falls on slower peripheral vascular, hip sales
10.09.2026 12:06
CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.
Pulmera Appoints Jared Slibeck Chief Commercial Officer
09.09.2026 12:58
Twenty-year industry veteran in surgical navigation and enabling technology joins Pulmera to spearhead commercial adoption of its CBeam™ 3D Imaging Platform, the first C-Arm Native 3D imaging system. 20-Year Stryker Veteran Jared Slibeck Joins Pulmera as Chief Commercial Officer Jared Slibeck has been named Chief Commercial Officer for Pulmera, effective September 1, 2026. Slibeck will lead the company’s commercial strategy and market development as the company brings the CBeam™ 3D Imaging Platf
Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?
04.09.2026 14:27
BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.
Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
14.08.2026 11:11
Boston Scientific (BSX) stock: EP/WATCHMAN slowdown drives discount valuation. See why itâs a Buyânew launches, insider buying, cost savings.
Stryker (NYSE:SYK): A Quality Investment for Long-Term Investors
14.08.2026 11:01
Stryker (SYK) passes the Caviar Cruise quality screen: strong growth, 36% ROIC, and solid cash conversion. A quality investing standout.
Can Stryker (SYK) Still Look Undervalued After Backlog Recovery?
14.08.2026 03:16
Stryker stock has delivered a 35.9% gain over the past five years, yet current checks suggest it is not an obvious bargain, even as an Intrinsic Value estimate using a Discounted Cash Flow (DCF) framework points to the shares trading below that intrinsic value by 19.8%. Stryker's 35.9% return over five years indicates the stock has rewarded long term holders. New investors now need to weigh valuation more carefully than during earlier stages of the move. Strong demand for Stryker's medical...
Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company
10.08.2026 18:14
Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.
Stryker declares an $0.88 per share quarterly dividend
05.08.2026 13:34
Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter. About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer
Stryker (SYK) Q2 2026 Earnings Call Transcript
04.08.2026 00:16
CEO Lobo discusses 9% organic sales growth and margin expansion amid cybersecurity recovery.
Stryker (NYSE:SYK): A Dividend Quality Play Built on Sustainability
03.08.2026 09:40
Discover why Stryker (SYK) passes a dividend screen: sustainable 1.01% yield, 7.89% growth, 38.99% payout, strong profitability. Health rating meets bar.
Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer
02.08.2026 14:08
Solventum (NYSE:SOLV) has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed current Controller and Chief Accounting Officer Mary Wilcox following her retirement. Zieselman brings experience from Surgery Partners Inc., Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya Inc., and is a licensed CPA. Solventum enters this leadership change with its stock at $85.44 and a value score of 5, which can help...
Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question?
02.08.2026 01:11
Stryker (SYK) is back in focus after its second quarter 2026 earnings, reporting sales of US$6.59b and net income of US$1.28b, alongside a sharp market reaction to the release. See our latest analysis for Stryker. The 1 day share price return of Stryker fell 6.42% on the earnings release, which pulled the year to date share price return down 6.46%, while the 5 year total shareholder return of 30.66% still reflects longer term gains. If Stryker’s move has you reassessing healthcare exposure,...